Open reference book with a red ribbon beside reading glasses and a small capped vial
What is an hct/p? The fda term that decides how banked fat is regulated 2

HCT/P stands for human cells, tissues, or cellular or tissue-based products, which 21 CFR 1271.3(d) defines as “articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient.” That one sentence is the HCT/P definition, and it turns on what the tissue is intended for. This post covers what the term takes in, what it leaves out, and why it matters for fat banking.

TLDR An HCT/P is human cells or tissue intended to be implanted, transplanted, infused, or transferred into a person. FDA’s guidance treats adipose tissue as structural tissue under that framework. Four criteria decide whether an HCT/P stays under the tissue rules alone or is regulated as a drug, device, or biological product. An HCT/P label is not FDA approval, and banking adipose tissue does not guarantee any future use.

Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.


You could take HCT/P for lab shorthand, a term that lives on a form and has nothing to do with you. I get why. It reads like a part number.

Here is what is actually the case. FDA’s tissue regulation is written around this term, and before anyone can say which rules apply to stored tissue, one question comes first. Is it an HCT/P?

What Does the HCT/P Definition Mean in Plain Words?

The HCT/P definition covers human cells or tissue that someone means to put into a person, with a few named exceptions. Go back to the sentence in the definitions section of FDA’s tissue regulation. It covers articles “intended for implantation, transplantation, infusion, or transfer into a human recipient.”

Translation: what the tissue is meant for is what makes it an HCT/P. That question about intent comes back when FDA sorts HCT/Ps into two groups.

Who regulates them? FDA’s tissue products page, current as of 03/01/2024, says the Center for Biologics Evaluation and Research regulates HCT/Ps under 21 CFR Parts 1270 and 1271.


What Counts as an HCT/P?

Anything that fits the definition and is not on the excluded list counts, and the regulation gives examples. The same paragraph says: “Examples of HCT/Ps include, but are not limited to, bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem/progenitor cells derived from peripheral and cord blood, manipulated autologous chondrocytes, epithelial cells on a synthetic matrix, and semen or other reproductive tissue.”

Here’s the problem. Fat is not on that list, and someone who stops at the examples could decide fat sits outside the rule. But the words “include, but are not limited to” tell you the list is open.

So where does fat come in? Through FDA’s July 2020 guidance, which says: “FDA considers adipose tissue to be a structural tissue for the purpose of applying the HCT/P regulatory framework.” If someone tells you the regulation itself lists fat, ask them to point to the line. The source for fat is the guidance.


What Is Not an HCT/P?

Eight kinds of articles are left out by name. The same paragraph says “The following articles are not considered HCT/Ps” and then lists them. The table below gives each one, trimmed for length.

ParagraphNot considered an HCT/P
(1)Vascularized human organs for transplantation
(2)Whole blood, blood components, or blood derivative products subject to listing under parts 607 and 207
(3)Secreted or extracted human products, such as milk, collagen, and cell factors; except that semen is considered an HCT/P
(4)Minimally manipulated bone marrow for homologous use and not combined with another article, apart from certain agents such as water
(5)Ancillary products used in the manufacture of HCT/P
(6)Cells, tissues, and organs derived from animals other than humans
(7)In vitro diagnostic products as defined in section 809.3(a)
(8)Blood vessels recovered with an organ, intended and labeled for use in organ transplantation only

Read the rows as written. Adipose tissue is not named in any of them.


How Does an HCT/P End Up Under Section 361 or Section 351?

Four criteria decide it, and an HCT/P has to meet all four to stay on the section 361 side. 21 CFR 1271.10(a) says an HCT/P “is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria”.

First, it is minimally manipulated. Second, it is intended for homologous use only, where the HCT/P “performs the same basic function or functions in the recipient as in the donor.” Third, it is not combined with another article, apart from water, crystalloids, or a sterilizing, preserving, or storage agent that raises no new clinical safety concerns. Fourth, it has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or it is for a use the rule lists, such as autologous use, where the tissue goes back into the person it came from.

What if it misses one? Then, unless an exception applies, 21 CFR 1271.20 says the HCT/P “will be regulated as a drug, device, and/or biological product under the act and/or section 351 of the PHS Act”. The same guidance adds that for such an HCT/P, “premarket review will be required.” People call the two sides “361 HCT/Ps” and “351 products”, which is shorthand and not regulation wording. Our posts on 361 versus 351 and the homologous use criterion go deeper.


Why Does the HCT/P Definition Matter If You Are Banking Fat?

It matters because the term decides which rules apply to the tissue and to the place that holds it. Start with the place. 21 CFR 1271.3(e) says “Manufacture means, but is not limited to, any or all steps in the recovery, processing, storage, labeling, packaging, or distribution of any human cell or tissue”. Storage is on that list, so a facility that only stores an HCT/P is a manufacturer under this rule.

Manufacturers of section 361 HCT/Ps have to register and list under 21 CFR 1271.10(b). Registration is not FDA approval, and neither is a listing or the HCT/P label itself. Our post on FDA establishment registration explains what registering does and does not tell you.

Now the tissue. Because FDA’s guidance treats fat as structural tissue, the structural-tissue test for minimal manipulation applies. 21 CFR 1271.3(f) defines that as “processing that does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement”. This is how I read the rule. For stored fat, the question is what the processing did to the tissue, and our post on what minimally manipulated means covers that test.

Does banked fat always meet all four criteria? No. FDA’s guidance gives adipose examples that do not. Which side of the fork a given tissue lands on depends on how it is processed and what it is intended for. A blog post cannot settle that.


What Should You Ask Once You Know What an HCT/P Is?

Ask three questions, in plain words. First, how will the tissue be processed, step by step? The minimal manipulation test is about processing, so a vague answer is not good enough.

Second, what do the paperwork and the marketing say the tissue is intended for? The rule reads intended use from “the labeling, advertising, or other indications of the manufacturer’s objective intent”.

Third, who stores the tissue, and is that facility registered and listed? Ask to see the registration.

Know who does what, too. Save My Fat is a connector that links patients and providers with a U.S.-based tissue bank. A partner provider collects the tissue, and the tissue bank processes and cryopreserves it. No adipose-derived product has FDA approval to treat any disease, so take any treatment question to your own licensed provider.


Frequently Asked Questions

Is fat an HCT/P under FDA’s rules?

The regulation’s examples do not name fat or adipose tissue, but the list is open. FDA’s July 2020 guidance applies the HCT/P framework to adipose tissue, as a structural tissue. Whether a specific article fits the definition turns on what it is intended for.

Does being an HCT/P mean a product has FDA approval?

No. HCT/P is a defined term that tells you which rules apply. A registration or a listing under those rules does not mean FDA approval, and neither does the HCT/P label.

Does storing tissue count as manufacturing an HCT/P?

Yes. The regulation’s definition of manufacture includes storage. Manufacturers of section 361 HCT/Ps have to register and list, and registration is not FDA approval.

Can banked fat be used for a treatment later?

No one can tell you that today. Any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time. Banking does not guarantee any future use, so take that question to your own licensed provider.


Key Takeaways

An HCT/P is human cells or tissue intended to go into a human recipient, so the definition turns on intended use. The regulation’s examples do not name fat. FDA’s guidance covers adipose tissue as a structural tissue. Four criteria decide whether an HCT/P is regulated solely under section 361 or as a drug, device, and/or biological product. Storage counts as manufacture, and registration is not FDA approval. Ask how the tissue will be processed, and take any treatment question to your own licensed provider.

Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

If you are thinking about adipose tissue banking for potential future use, look over current pricing or ask your questions through the contact page.


Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.

This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.

About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

Related guide: FDA adipose tissue regulation.